Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Equity Average (2016 - 2025)

Historic Equity Average for CytomX Therapeutics (CTMX) over the last 11 years, with Q3 2025 value amounting to $113.6 million.

  • CytomX Therapeutics' Equity Average rose 51569.71% to $113.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.6 million, marking a year-over-year increase of 51569.71%. This contributed to the annual value of -$24.0 million for FY2024, which is 6403.62% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Equity Average of $113.6 million as of Q3 2025, which was up 51569.71% from $72.5 million recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Equity Average high stood at $113.6 million for Q3 2025, and its period low was -$86.2 million during Q1 2023.
  • Over the past 5 years, CytomX Therapeutics' median Equity Average value was -$27.3 million (recorded in 2024), while the average stood at -$12.9 million.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 65480.27% in 2022, then soared by 51569.71% in 2025.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Equity Average stood at $15.0 million in 2021, then crashed by 654.8% to -$83.1 million in 2022, then surged by 40.66% to -$49.3 million in 2023, then soared by 75.77% to -$12.0 million in 2024, then soared by 1050.72% to $113.6 million in 2025.
  • Its last three reported values are $113.6 million in Q3 2025, $72.5 million for Q2 2025, and $12.3 million during Q1 2025.